Drugs in the Pipeline
FDA Grants Xalkori Priority Review for Non-Small Cell Lung Cancer
The FDA has accepted and granted Priority Review for a supplemental New Drug Application (sNDA) for Xalkori (crizotinib; Pfizer).
Your search for non small cell lung cancer returned 109 results
Drugs in the Pipeline
Phase 3 Trial Update of Sorafenib for Advanced Non Small-cell Lung Cancer
Sorafenib does not improve OS for patients with advanced NSCLC, but it may benefit a subset of patients whose tumors harbor EGFR mutations.
Drugs in the Pipeline
Phase 2b Trial Update of Bavituximab for Second-Line Non-Small Cell Lung Cancer
Peregrine Pharmaceuticals announced interim results from its randomized, double-blind, placebo-controlled Phase 2b trial of bavituximab in patients with refractory non-small cell lung cancer (NSCLC).
Drugs in the Pipeline
Phase 3 Trial Update of Alimta for Nonsquamous Non-Small Cell Lung Cancer
Eli Lilly and Company announced today that the Phase 3 POINTBREAK trial did not meet its primary endpoint of improved overall survival for patients with nonsquamous non-small cell lung cancer (NSCLC) who were randomized to receive a combination of Alimta (pemetrexed for injection) with bevacizumab (Avastin; Genentech) and carboplatin induction followed by Alimta plus bevacizumab maintenance-the Alimta arm-compared to the combination of paclitaxel (Taxol; Bristol-Myers Squibb) with bevacizumab and carboplatin followed by bevacizumab maintenance-the paclitaxel arm.
Drugs in the Pipeline
Phase 3 Trial Update of Afatinib for Advanced non-Small Cell Lung Cancer
Boehringer Ingelheim announced results from its LUX-Lung 3 Phase 3 clinical trial of afatinib in patients with advanced non-small cell lung cancer (NSCLC).
Drugs in the Pipeline
Durvalumab Plus Chemo Granted Priority Review for Biliary Tract Cancer
The sBLA was supported by data from the phase 3 TOPAZ-1 trial.
Drugs in the Pipeline
FDA Rejects Sintilimab Combo for First-Line Treatment of Nonsquamous NSCLC
Sintilimab is an investigational programmed death receptor-1 (PD-1) inhibitor.
Drugs in the Pipeline
Improved Overall Survival With Cemiplimab in Cervical Cancer Trial
The phase 3 trial evaluated the efficacy and safety of cemiplimab in women 18 years of age and older with recurrent or metastatic cervical cancer, including those with either squamous cell carcinoma or adenocarcinoma.
Drugs in the Pipeline
Imfinzi Receives Orphan Drug Designation for Small Cell Lung Cancer
The FDA has granted Orphan Drug designation to Imfinzi (durvalumab; AstraZeneca) for the treatment of small cell lung cancer (SCLC).
Drugs in the Pipeline
RET Inhibitor Gets Breakthrough Tx Status for NSCLC, Medullary Thyroid Cancer
LOXO-292 is being evaluated in the ongoing Phase 1/2 LIBRETTO-001 clinical trial.
